Hypermethylation of the *hMLH1* gene promoter in solitary and multiple gastric cancers with microsatellite instability

K Sakata¹, G Tamura^{*,1}, Y Endoh¹, K Ohmura¹, S Ogata¹ and T Motoyama¹

¹Department of Pathology, Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585, Japan

Human cancers with a high frequency microsatellite instability phenotype develop due to defects in DNA mismatch repair genes. Silencing of a DNA mismatch repair gene, *hMLH1* gene, by promoter hypermethylation is a frequent cause of the microsatellite instability-H phenotype. Using methylation specific PCR we investigated the methylation status of the *hMLH1* gene promoter in 17 solitary gastric cancers (12 microsatellite instability-H and five microsatellite stable tumours from 17 patients), and 13 multiple gastric cancers (eight microsatellite instability-H, one low frequency microsatellite instability-L and four microsatellite stable tumours from five patients) and also examined non-cancerous gastric mucosa both adjacent to and distant from each tumour. Expression of *hMLH1* protein was evaluated by immunohistochemistry. All microsatellite instability-H tumours (20 out of 20) had evidence of methylation of *hMLH1* promoter, whereas only one out of 10 microsatellite instability-L and microsatellite stable tumours did ($P < 0.0000005$), and the methylation status correlated with *hMLH1* protein expression ($P < 0.000003$). Furthermore, methylation of the *hMLH1* promoter was detected in 50% (6 out of 12) and 63% (5 out of 8) of non-cancerous gastric mucosa samples adjacent to, and in 33% (4 out of 12) and 40% (2 out of 5) of those obtained from distant portion of, solitary and multiple cancers with microsatellite instability-H. Thus both solitary and multiple gastric cancers with microsatellite instability-H have evidence of similar high levels of *hMLH1* promoter hypermethylation in the surrounding non-cancerous tissue. Hypermethylation of the *hMLH1* promoter occurs in non-cancerous gastric mucosa of microsatellite instability-H tumours and may increase the risk of subsequent neoplasia.

British Journal of Cancer (2002) 86, 564–567. DOI: 10.1038/sj/bjc/6600076 www.bjcancer.com

© 2002 Cancer Research UK

Keywords: gastric cancer; *hMLH1*; hypermethylation; multiple cancer

Microsatellite instability (MSI) due to defects in mismatch repair genes such as *hMLH1* and *hMSH2* is now widely recognized as an important mechanism in tumorigenesis (Aaltonen *et al*, 1993; Ionov *et al*, 1993; Thibodeau *et al*, 1996; Fleisher *et al*, 1999; Kang *et al*, 1999; Leung *et al*, 1999; Suzuki *et al*, 1999; Toyota *et al*, 1999a). MSI is reportedly present in 15–33% of solitary gastric cancers, although mutations of the *hMLH1* or *hMSH2* genes are rare in sporadic gastric cancers (Chong *et al*, 1994; Mironov *et al*, 1994; Strickler *et al*, 1994; Tamura *et al*, 1996). Hypermethylation of promoter region CpG islands is a common mechanism by which tumour suppressor or tumour-related genes, and DNA mismatch repair genes are inactivated (Herman *et al*, 1995, 1998; Kane *et al*, 1997; Baylin *et al*, 1998; Jones and Laird, 1999). Aberrant DNA methylation of promoter region CpG islands of several genes, including *retinoblastoma* (*Rb*), *von Hippel-Lindau* (*VHL*), *p16*, *p15*, *APC*, *E-cadherin* and *hMLH1* has been reported in human cancers, and silencing of *hMLH1* by promoter hypermethylation is the major causative event in the development of human cancers with MSI phenotype, including gastric cancers (Graff *et al*, 1997; Kane *et al*, 1997; Herman *et al*, 1998; Fleisher *et al*, 1999; Kang *et al*, 1999; Leung *et al*, 1999; Suzuki *et al*, 1999; Tamura *et al*, 2000; Tsuchiya *et al*, 2000).

To clarify the role of hypermethylation of the *hMLH1* gene promoter in the development of multiple gastric cancers, we compared both the methylation status and expression of the

hMLH1 gene, in solitary and multiple gastric cancers with and without MSI. In addition, we examined the methylation status of the *hMLH1* gene in non-cancerous gastric mucosa adjacent to and distant from each tumour.

MATERIALS AND METHODS

Samples and DNA extraction

Thirty gastric adenocarcinomas, including 17 solitary tumours from 17 patients and 13 multiple tumours from five patients were studied. The patients ranged in age from 59 to 84 years (average 72 years). We also examined non-cancerous gastric tissue both adjacent to (at a distance of 2 mm) and distant from (at a distance of 5 cm or surgical margin) each tumour. The tumours were histologically differentiated adenocarcinomas comprising 28 early cancers (depth of invasion limited to the mucosa or submucosa) and two advanced cancers. Specimens were fixed in 10% buffered formalin. The carcinomas were cut serially into 5 mm slices in parallel with the lesser curvature and then embedded in paraffin. From one block that included the maximum diameter of the tumour, we prepared two sets of 3 and 10 μ m thick serial sections. The 3 μ m thick sections were used for haematoxylin-eosin and immunohistochemical stainings, and each set of the 10 μ m thick sections for DNA extraction of cancerous or non-cancerous DNA. To avoid contamination, either of cancerous or non-cancerous the area was carefully dissected using disposable scalpels by a reference to the serial haematoxylin-eosin stained sections under the microscope. DNA extraction was as described by Goelz

*Correspondence: G Tamura; E-mail: gtamura@med.id.yamagata-u.ac.jp

Received 3 October 2001; accepted 14 November 2001

et al (1985). All samples had been previously screened for MSI using 12 microsatellite markers, i.e. D2S115, D4S404, D5S178, IL9, D6S265, D7S490, D11S900, MYH6, TP53, D17S1176, D18S46, and D21S1407, and defined as MSI-H if there were more than 30% unstable loci, MSI-L less than 30% unstable loci, and microsatellite stable (MSS) no unstable loci (Ohmura *et al*, 2000; Ogata *et al*, 2001). Our samples constituted of 20 (12 solitary and eight multiple) MSI-H tumours, 1 MSI-L tumour and nine (five solitary and four multiple) MSS tumours.

Methylation-specific PCR

hMLH1 gene promoter methylation patterns were determined by methylation specific PCR (MSP), as described previously (Fleisher *et al*, 1999). MSP distinguishes unmethylated from methylated alleles of a given gene based on sequence changes that are produced following bisulfite treatment of DNA, which converts unmethylated cytosines to uracils, while leaving methylated cytosines unaffected. Subsequent PCR using primers specific to sequences that correspond to either methylated or unmethylated *hMLH1* gene promoter DNA was performed. The primer sequences of *hMLH1* for the unmethylated reaction were 5'-TTT TGA TGT AGA TGT TTT ATT AGG GTT GT-3' (sense) and 5'-ACC ACC TCA TCA TAA CTA CCC ACA-3' (antisense), whereas for the methylated reaction they were 5'-ACG TAG ACG TTT TAT TAG GGT CGC-3' (sense) and 5'-CCT CAT CGT AAC TAC CCG CG-3' (antisense) (Fleisher *et al*, 1999). Briefly, 2 µg of genomic DNA was denatured by treatment with NaOH and modified by sodium bisulfite. DNA samples were then purified using a Wizard DNA purification resin (Promega, Madison, WI, USA), treated with NaOH, precipitated with ethanol, and resuspended in 30 µl water. Modified DNA was amplified in a total volume of 20 µl using GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City, CA, USA) containing 1.0 mM MgCl₂, 20 µM of each primer, 0.2 mM dNTPs, and 1 unit of Taq polymerase (AmpliAmp Gold DNA Polymerase, PE Applied Biosystems). After activation of the Taq polymerase at 95°C for 10 min, PCR was performed in a thermal cycler (GeneAmp 9700, PE Applied Biosystems) for 35 cycles, each cycle consisting of denaturation at 95°C for 15 s, annealing at 55°C for 15 s, and extension at 72°C for 30 s, followed by a final 7 min extension at 72°C. The PCR products were then loaded onto a non-denaturing 6% polyacrylamide gel, stained with ethidium bromide, and visualized under UV illumination.

Immunohistochemistry

Immunohistochemistry was performed on formalin-fixed, paraffin embedded sections using a standard labelled streptavidin-biotin system (Nichirei, Tokyo, Japan). Mouse monoclonal antibody to the *hMLH1* gene product, G168-728 (PharMingen, San Diego, CA, USA), was used at 1:50 dilution after antigen retrieval by microwave.

Statistical analysis

Statistical comparisons were performed using Fisher's exact test. *P* values <0.05 were considered significant.

RESULTS

Hypermethylation of the *hMLH1* gene promoter was detected in all solitary (12 out of 12) and multiple (8 out of 8) gastric cancers with MSI-H (Figure 1 and Table 1). Methylated alleles were found in none (0 out of 5) of solitary and 20% (1 out of 5) of multiple MSI-L and MSS tumours (Table 1). The MSI-L tumour did not have methylated *hMLH1* gene promoter alleles. The methylation status of the *hMLH1* promoter was significantly correlated with MSI status (*P*<0.000005). Methylated *hMLH1* alleles were also

Figure 1 Representative results from methylation-specific PCR (MSP) of the *hMLH1* gene promoter in multiple (**A**) and solitary (**B**) gastric cancers. The presence of PCR product in lanes marked M indicates hypermethylated *hMLH1* product, lanes marked U indicate unmethylated *hMLH1*. T, Tumour DNA; A, normal mucosa adjacent to tumour; N, normal mucosa from the surgical margin; PC, positive control; NC, negative control; SM, size marker.

Table 1 Frequencies of *hMLH1* promoter hypermethylation in solitary and multiple gastric cancers and noncancerous mucosa

MSI status	Tumour	Normal 1	Normal 2
Solitary			
MSI-H	100% (12/12)	50% (6/12)	33% (4/12)
MSS	0% (0/5)	0% (0/5)	20% (1/5)
Multiple			
MSI-H	100% (8/8)	63% (5/8)	40% (2/5)
MSI-L and MSS	20% (1/5)	20% (1/5)	

Normal 1, non-cancerous mucosae adjacent to each tumour; Normal 2, non-cancerous mucosae at surgical margin from each patient (17 patients with solitary tumour and five patients with multiple tumour).

present in 50% (6 out of 12) and 63% (5 out of 8) of samples of non-cancerous gastric mucosa adjacent to, and in 33% (4 out of 12) and 40% (2 out of 5) samples of non-cancerous gastric mucosa distant from solitary and multiple gastric cancers with MSI-H (Table 1). In contrast, methylated alleles were infrequently present in none (0 out of 5) of non-cancerous mucosa adjacent to, and in 20% (1 out of 5) of non-cancerous mucosa distant from solitary gastric cancers with MSS (Table 1). Most of the methylated tumours (12 out of 12 solitary tumours and 7 out of 9 (78%) of multiple tumours) showed an apparent loss of *hMLH1* protein expression (Figure 2). All nine unmethylated tumours (five solitary and four multiple tumours) and their surrounding non-cancerous mucosa had a normal expression level of *hMLH1* protein. The methylation status of the *hMLH1* promoter was significantly correlated with protein expression in solitary and multiple tumours (*P*<0.000003, Table 2).

DISCUSSION

MSI is found in 15–33% of sporadic gastric cancers, a higher incidence than that seen in other types of sporadic human cancers (Chong *et al*, 1994; Mironov *et al*, 1994; Strickler *et al*, 1994; Tamura *et al*, 1996; Ohmura *et al*, 2000). Furthermore, multiple gastric cancers have a higher incidence of MSI than solitary gastric cancers, although few studies have focused on the relationship between multiple gastric cancers and MSI (Nakashima *et al*,

REFERENCES

- Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A (1993) Clues to the pathogenesis of familial colorectal cancer. *Science* **260**: 812–816
- Ahuja N, Mohan AL, Li Q, Stalker JM, Herman JG, Hamilton SR, Baylin SB, Issa JP (1997) Association between CpG island methylation and microsatellite instability in colorectal cancer. *Cancer Res* **57**: 3370–3374
- Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP (1998) Aging and DNA methylation in colorectal mucosa and cancer. *Cancer Res* **58**: 5489–5494
- Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. *Adv Cancer Res* **72**: 141–196
- Chong JM, Fukuyama M, Hayashi Y, Takizawa T, Koike M, Konishi M, Kikuchi-Yanoshita R, Miyaki M (1994) Microsatellite instability in the progression of gastric carcinoma. *Cancer Res* **54**: 4595–4597
- Deng G, Chen A, Hong J, Chae HS, Kim YS (1999) Methylation of CpG in a small region of the hMLM1 promoter invariably correlates with the absence of gene expression. *Cancer Res* **59**: 2029–2033
- dos Santos NR, Seruca R, Constança M, Seixas M, Sobrinho-Simões M (1996) Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. *Gastroenterology* **110**: 38–44
- Esaki Y, Hirokawa K, Yamashiro M (1987) Multiple gastric cancers in the aged with special reference to intramucosal cancers. *Cancer* **59**: 560–565
- Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. *Cancer Res* **59**: 1090–1095
- Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, James SP, Wilson KT, Herman JG, Meltzer SJ (2001) Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. *Oncogene* **20**: 329–335
- Goelz SE, Hamilton SR, Vogelstein B (1985) Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. *Biochem Biophys Res Commun* **130**: 118–126
- Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM (1997) Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. *J Biol Chem* **272**: 22322–22329
- Guo RJ, Arai H, Kitayama Y, Igarashi H, Hemmi H, Arai T, Hanai H, Sugimura H (2001) Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa. *Pathol Int* **51**: 240–247
- Halling KC, Harper J, Moskaluk CA, Thibodeau SN, Petroni GR, Yustein AS, Tosi P, Minacci C, Roviello F, Piva P, Hamilton SR, Jackson CE, Powell SM (1999) Origin of microsatellite instability in gastric cancer. *Am J Pathol* **155**: 205–211
- Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res* **55**: 4525–4530
- Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA* **95**: 6870–6875
- Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for clonal carcinogenesis. *Nature* **363**: 558–561
- Issa JP (2000) CpG-island methylation in aging and cancer. *Curr Top Microbiol Immunol* **249**: 101–118
- Jones PA, Laird PW (1999) Cancer epigenetics comes of age. *Nat Genet* **21**: 163–167
- Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. *Cancer Res* **57**: 808–811
- Kang GH, Shim YH, Ro JY (1999) Correlation of methylation of the hMLH1 promoter with lack of expression of hMLH1 in sporadic gastric carcinomas with replication error. *Lab Invest* **79**: 903–909
- Kuismanen SA, Holmberg MT, Salovaara R, Schweizer P, Aaltonen LA, de la Chapelle A, Nystrom-Lahti M, Peltomäki P (1999) Epigenetic phenotypes distinguish microsatellite-stable and -unstable colorectal cancers. *Proc Natl Acad Sci USA* **96**: 12661–12666
- Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. *Cancer Res* **59**: 159–164
- Leung WK, Yu J, Ng EKW, To KF, Ma PK, Lee TL, Go MYY, Chung SCS, Sung JY (2001) Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. *Cancer* **91**: 2294–2301
- Lipkin M (1988) Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. *Cancer Res* **48**: 235–245
- Mironov NM, Aguelon MA, Potapova GI, Omori Y, Gorbunov OV, Klimenkov AA, Yamasaki H (1994) Alterations of (CA)_n DNA repeats and tumor suppressor genes in human gastric cancer. *Cancer Res* **54**: 41–44
- Nakagawa H, Chadwick RB, Peltomäki P, Plass C, Nakamura Y, de la Chapelle A (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. *Proc Natl Acad Sci USA* **98**: 591–596
- Nakashima H, Inoue H, Mori M, Ueo H, Ikeda M, Akiyoshi T (1995) Microsatellite instability in Japanese gastric cancer. *Cancer* **75**: 1503–1507
- Ogata S, Tamura G, Endoh Y, Sakata K, Ohmura K, Motoyama T (2001) Microsatellite alterations and target gene mutations in the early stages of multiple gastric cancer development. *J Pathol* **194**: 334–340
- Ohmura K, Tamura G, Endoh Y, Sakata K, Takahashi T, Motoyama T (2000) Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. *Hum Pathol* **31**: 1031–1035
- Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D (1994) p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. *Cancer Res* **54**: 4750–4755
- Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y, Imai K (1999) Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. *Int J Cancer* **83**: 309–313
- Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Terashima M, Eda Y, Satodate R (1996) Allelotype of adenoma and differentiated adenocarcinoma of the stomach. *J Pathol* **180**: 371–377
- Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M, Motoyama T, Meltzer SJ (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. *J Natl Cancer Inst* **92**: 569–573
- Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, Honchel R, Halling KC (1996) Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. *Cancer Res* **56**: 4836–4840
- Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999a) CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci USA* **96**: 8681–8686
- Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP (1999b) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res* **59**: 5438–5442
- Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ (2000) Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. *Oncogene* **19**: 3642–3646
- Yamashita K, Arimura Y, Kurokawa S, Itoh F, Endo T, Hirata K, Imamura A, Kondo M, Sato T, Imai K (2000) Microsatellite instability in patients with multiple primary cancers of the gastrointestinal tract. *Gut* **46**: 790–794
- Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD (1998) Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. *Proc Natl Acad Sci USA* **95**: 8698–8702